You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Generation of Human Hepatocytes
SBC: IN VIVO TECHNOLOGIES Topic: N/ADESCRIPTION (provided by applicant): The goal of this project is to produce "humanized" livers in large animal models such as sheep and pigs that can serve as a reliable source of significant numbers of functional human hepatocytes. The isolated human hepatocytes and/or "humanized" livers can be used for drug toxicity studies as well as for possible clinical use in patients with liver failure. Tra ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
CLINICAL EVALUATION OF A DEVICE TO REDUCE PATIENT FALLS
SBC: NOC WATCH, INC Topic: N/ADESCRIPTION (provided by applicant): Falls are the leading cause of US injury deaths among people 65 and older, and at least two of every three residents of skilled nursing facilities (SNF) fall at least once each year. This Phase I study will assess
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Plasma Diagnostic for Alzheimer's Disease Pathology
SBC: SAMARITAN PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): Presently, there exists no simple minimally invasive test, such as a blood test, that can differentiate patients affected by Alzheimer's disease (AD) from healthy individuals. Our long-term goal is to develop new strategies for determining prognosis or predicting response to therapy. This will provide tools to improve clinical decision-making in the care of AD ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
SP004, a sigma-1 ligand with AchE inhibition properties
SBC: SAMARITAN PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): The acetylcholinesterase inhibitors (AchEI) are currently the most broadly used drugs to treat AIzheirmer's disease (AD). Unfortunately none of the beneficial effect lasts for more than a short two years time period, probably due to the progressive degeneration of the cholinergic neurons. This indicates that aiming at the same time at another target distinct to ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Plasma Diagnostic for Alzheimer's Disease Pathology
SBC: SAMARITAN PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): Presently, there exists no simple minimally invasive test, such as a blood test, that can differentiate patients affected by Alzheimer's disease (AD) from healthy individuals. Our long-term goal is to develop new st
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Generation of Human Hepatocytes
SBC: IN VIVO TECHNOLOGIES Topic: N/ADESCRIPTION (provided by applicant): The goal of this project is to produce "humanized" livers in large animal models such as sheep and pigs that can serve as a reliable source of significant numbers of functional human hepatocytes. The isolated human
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
SP004, a sigma-1 ligand with AchE inhibition properties
SBC: SAMARITAN PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): The acetylcholinesterase inhibitors (AchEI) are currently the most broadly used drugs to treat AIzheirmer's disease (AD). Unfortunately none of the beneficial effect lasts for more than a short two years time perio
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
